PharmaCyte Biotech, Inc.
PMCB Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$0.35
KIRA · Stoqly’s AI analyst, in plain words
- PharmaCyte Biotech, Inc. had $0.0M of revenue in fiscal 2026.
- PharmaCyte Biotech, Inc. lost $19.4M in fiscal 2026.
- PharmaCyte Biotech, Inc. returned $0.4M to shareholders in fiscal 2026. The diluted share count rose 14.3%.
Market cap
$3.8M
P/E
—
Revenue
$0.0M
Net income
−$19.4M
Free cash flow
—
Operating margin
—
PharmaCyte Biotech, Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$19.4M
No. It lost money last year.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What PharmaCyte Biotech, Inc. does
No business description yet.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jul 29, 2026
- Legal name
- PharmaCyte Biotech, Inc.
- CIK
- 0001157075
PharmaCyte Biotech, Inc. · PMCB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$4.2M | −$4.3M | $0.3M | $30.7M | −$19.4M |
| Diluted EPS | −$0.27 | −$0.22 | −$1.80 | $3.19 | −$2.77 |
| Cash | |||||
| Cash from operations | −$4.1M | −$3.8M | −$2.2M | −$3.0M | −$5.2M |
| Share buybacks | $0.0M | $13.6M | $28.2M | $2.5M | $0.4M |
| Share count change | 971.7% | 25.6% | −50.8% | −23.5% | 14.3% |
| Debt and strength | |||||
| Cash and short-term investments | $85.4M | $68.0M | $50.2M | $15.5M | $18.9M |
| Shareholders' equity | $89.9M | $72.7M | $27.6M | $51.9M | $33.3M |
| Current ratio | 121.4x | 116.2x | 6.8x | 7.7x | 45.3x |
| Interest coverage | −8,784.0x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −8.8% | −5.3% | 0.7% | 77.1% | −45.6% |
| Return on tangible equity | −4.9% | −6.2% | −66.0% | 46.4% | −69.7% |
| Piotroski F-score | 3 | 1 | 3 | 4 | 2 |
| Altman Z'' | 135.8 | 130.4 | −1.1 | 13.4 | −0.2 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
PharmaCyte Biotech, Inc. · PMCB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.35 a share, the company is worth $3.8M.
Source: SEC EDGAR XBRL filings (CIK 0001157075). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.